Patents Assigned to Virobay, Inc.
  • DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
    Publication number: 20140221478
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: ViroBay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
  • Di-fluoro containing compounds as cysteine protease inhibitors
    Patent number: 8748649
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: June 10, 2014
    Assignee: Virobay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
  • Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
    Patent number: 8680152
    Abstract: The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: March 25, 2014
    Assignee: Virobay, Inc.
    Inventor: Robert Booth
  • DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
    Publication number: 20140018421
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: December 18, 2012
    Publication date: January 16, 2014
    Applicant: ViroBay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
  • HCV inhibitors
    Patent number: 8518874
    Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: August 27, 2013
    Assignee: Virobay, Inc.
    Inventors: Michael Graupe, John O. Link, Chandrasekar Venkataramani
  • Alpha ketoamide compounds as cysteine protease inhibitors
    Patent number: 8450373
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: May 28, 2013
    Assignee: Virobay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
    Patent number: 8431733
    Abstract: The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides, and their use in the preparation of HCV inhibitors and cathepsin inhibitors.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: April 30, 2013
    Assignee: Virobay, Inc.
    Inventor: Jeffrey Dener
  • Di-fluoro containing compounds as cysteine protease inhibitors
    Patent number: 8367732
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: February 5, 2013
    Assignee: Virobay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
  • CATHEPSIN INHIBITORS FOR TREATING MICROGLIA-MEDIATED NEURON LOSS IN THE CENTRAL NERVOUS SYSTEM
    Publication number: 20120329837
    Abstract: The present invention concerns methods of using Cathepsin S inhibitors and compounds of Formula I that are inhibitors of cathepsin S in treating CNS disorders, diseases, and injuries, particularly neurodegenerative conditions. The present invention is directed to pharmaceutical compositions comprising these compounds for treating CNS disorders.
    Type: Application
    Filed: June 18, 2012
    Publication date: December 27, 2012
    Applicant: ViroBay, Inc.
    Inventor: Robert Booth
  • Process for the preparation of ()-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
    Patent number: 8324417
    Abstract: The present invention relates to a process for the preparation of alkyl esters of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid, which are intermediates useful in the synthesis of (S)—N-(1-cyanocyclopropyl)-5-cyclopropyl-4,4-difluoro-2-((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethylamino)pentanamide and related compounds, which are compounds that are cysteine protease inhibitors.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: December 4, 2012
    Assignee: ViroBay, Inc.
    Inventors: Barry Hart, Jeff Dener, Michael Green, Michael Standen, Oldrich Kocian
  • CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN
    Publication number: 20120282267
    Abstract: The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.
    Type: Application
    Filed: May 2, 2012
    Publication date: November 8, 2012
    Applicant: ViroBay, Inc.
    Inventor: Robert Booth
  • ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
    Publication number: 20120190714
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: July 27, 2011
    Publication date: July 26, 2012
    Applicants: Applera Corporation, ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Inhibitors of cathepsin B
    Patent number: 8211897
    Abstract: The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: July 3, 2012
    Assignee: ViroBay, Inc.
    Inventor: Leslie Holsinger
  • Sulfonamide compounds as cysteine protease inhibitors
    Patent number: 8163735
    Abstract: The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: April 24, 2012
    Assignee: Virobay, Inc.
    Inventors: Soon H. Woo, Randall W. Vivian, John O. Link
  • Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
    Patent number: 8143448
    Abstract: The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides as well as novel compounds prepared or used in the process.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: March 27, 2012
    Assignee: ViroBay, Inc.
    Inventor: Jeffrey Dener
  • Substituted pyrazines that inhibit protease cathepsin S and HCV replication
    Patent number: 8106059
    Abstract: The present invention is directed to compounds of formula I, below, that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease, and autoimmune disorders. The present invention is also directed to pharmaceutical compositions containing these compounds, and processes for preparing the compounds.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: January 31, 2012
    Assignee: ViroBay, Inc.
    Inventors: Leslie Jean Holsinger, Kyle Elrod, John O. Link, Michael Graupe, In Jong Kim
  • SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
    Publication number: 20110281879
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: January 12, 2011
    Publication date: November 17, 2011
    Applicant: ViroBay, Inc.
    Inventor: Craig Mossman
  • Alpha ketoamide compounds as cysteine protease inhibitors
    Patent number: 8013183
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: September 6, 2011
    Assignee: ViroBay, Inc.
    Inventors: Michael Graupe, John O. Link, Michael G. Roepel
  • Haloalkyl containing compounds as cysteine protease inhibitors
    Patent number: 8013186
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: September 6, 2011
    Assignee: Virobay, Inc.
    Inventor: Eduardo L. Setti
  • DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
    Publication number: 20110172310
    Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
    Type: Application
    Filed: January 11, 2011
    Publication date: July 14, 2011
    Applicant: ViroBay, Inc.
    Inventors: John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo